FIG. 1.

Progression-free and overall survival based on preoperative CgA and PST levels. The survival of patients with normal preoperative levels (blue solid line) are compared with those of patients with high levels (elevated above reference range, red dashed lines). The patients with elevated preoperative CgA had decreased (a) PFS (median PFS, 39.7 vs 98.1 months; p < 0.01) and (b) OS (median OS, 87.8 vs not reached; p = 0.01), and those with elevated postoperative PST also had decreased (c) PFS (median PFS, 31.0 vs 141.1 months; p < 0.01) and (d) OS (median OS, 85.1 months vs not reached, p < 0.01). CgA, chromogranin A; PST, pancreastatin; PFS, progression-free survival; OS, overall survival